Bimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials

Main Article Content

Andreas Pinter
Department of Dermatology, Venereology and Allergology, Goethe-University

Bruce Strober
Yale University School of Medicine

David Rosmarin
Tufts Medical Center Department of Dermatology

Paolo Gisondi
Dermatology and Venereology, Department of Medicine, Università di Verona

Veerle Vanvoorden
UCB Pharma

Luke Peterson
UCB Pharma

Cynthia Madden
UCB Pharma

Dirk de Cuyper
UCB Pharma

Richard B Warren
Dermatology Centre, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester

Keywords

bimekizumab, psoriasis, moderate to severe, phase 3, clinical trial, pooled results, bodyweight, dosing

Abstract

N/A

References

1. Puig L. J Eur Acad Dermatol 2011;25:1,007–011

2. Warren RB. N Engl J Med 2021;385:130–41

3. Reich K. Lancet 2021;397:487–98

4. Reich K. N Engl J Med 2021;385:142–52

5. Gordon KB. Lancet 2021;397:475–86

Article Sidebar

Poster PDF
Published
Nov 16, 2022
DOI https://doi.org/10.25251/skin.6.supp.73

Article Details

How to Cite
Pinter, A., Strober, B., Rosmarin, D., Gisondi, P., Vanvoorden, V., Peterson, L., Madden, C., de Cuyper, D., & Warren, R. B. (2022). Bimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials. SKIN The Journal of Cutaneous Medicine, 6(6), s73. https://doi.org/10.25251/skin.6.supp.73
Issue
Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Section
Poster Presentations from FC22 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>